ヘパリンコファクターIIは,高齢者の頸動脈動脈硬化に対する新しい保護因子です
Ken-ichi Aihara1, Hiroyuki Azuma, Nobuyuki Takamori
1Department of Medicine and Bioregulatory Sciences, University of Tokushima, Graduate School of Medicine, Kuramoto-cho Tokushima, Japan.
Circulation
|May 19, 2004
まとめ
ヘパリンコファクターII (HCII) の活性が動脈硬化症を予防する可能性があります. 高濃度なHCIIは,頸動脈板の厚さの減少と相関しており,高齢者ではHDLコレステロールよりも強い抗アテロゲン系因子であることを示唆しています.
科学分野:
- 心血管研究 循環器科の研究
- バイオケミストリー バイオケミストリー
- ゲロントロジーはゲロントロジーの学科です.
背景:
- トロンビンはアテロトロンボシスの鍵です.
- ヘパリンコファクターII (HCII) は,動脈損傷部位でトロンビンを抑制する.
- HCIIは,血管トロンビン活動を調節する可能性があります.
研究 の 目的:
- 動脈硬化に対する予防因子としてのプラズマHCII活性を調べる.
- 既存の血管損傷を有する高齢者におけるHCIIの役割を評価する.
主な方法:
- 超音波検査は,306人の日本人の高齢者において,大動脈の最大プラーク厚さ (MPT) を測定した.
- 統計分析では,血のHCII活性を含む心血管リスク要因を,MPTと比較して評価した.
- リグレッション分析により,MPTの独立した予測要因が特定されました.
主要な成果:
- 血のHCII活動は,年齢とともに減少した.
- リポプロテイン (a),HbA1c,糖尿病はMPTを増加させた.
- 高密度脂質タンパク質 (HDL) コレステロールとHCIIの活動は,MPTと負の相関関係にあった.
- HCII活性とHDLコレステロールは独立してMPTを抑制し,HCIIはより強い要因であった.
結論:
- HCIIは,新しく独立した抗アテロゲン系因子です.
- 高齢者の頸動脈動脈硬化に対するHCIIは,HDLコレステロールよりも強力な予測因子です.
関連する概念動画
Anticoagulant Drugs: Low-Molecular-Weight Heparins
2.6K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.6K
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.7K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.7K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
1.6K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.6K
Coronary Artery Disease II: Pathophysiology
1.1K
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
1.1K
Atherosclerosis III: Management
741
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
741
Venous Thrombosis III: Interprofessional Care
482
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
482


